StockData
Puma Biotechnology, Inc. logo

Puma Biotechnology, Inc. (PBYI) stock

PBYINasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 14/3019% below fair value
$7.22+0.08 (+1.12%)

Close on Nov 18, 2026Market cap $372.70MP/E 13.9Yield –

How the market prices Puma Biotechnology

Each ratio against its own distribution since 2016, from month-end prices and the figures reported at the time

Puma Biotechnology trades at 13.9× its earnings, against a median of 11.8× since 2016 — on the expensive side of its own range.

The shaded bar covers the 5th to 95th percentile of month-end values since 2016, the darker part the 25th to 75th, the line the median and the dot today. The figure on the right is the percentile today sits at.

Price to earnings since 2016

Median 11.8×, today 13.9×

What Puma Biotechnology keeps of every dollar

Trailing twelve months, from revenue down to net income. Grey columns are what comes out.

Margins against the industry

Gross margin74.8%vs 52.8%
Operating margin13.2%vs -42.9%
EBITDA margin17.7%vs -29.3%
Pretax margin13.5%vs -13.0%
Net margin11.6%vs -39.9%
Free cash flow margin17.8%vs -9.41%

The grey tick and the second figure are the median of companies in the same industry group; green means this company is on the better side of it.

What it earns on the capital it uses

Trailing twelve months over average capital

Return on invested capital is 42.7% against an estimated cost of capital of 10.0%: a spread of 32.7 points in the company's favour.

Return on equity22.0%vs -53.3%
Return on assets13.8%vs -40.6%
Return on invested capital42.7%vs -31.9%
Return on capital employed21.3%vs -38.7%

How hard the assets work

Revenue per dollar of assets1.19vs 0.39
Inventory turns a year5.31vs 2.68
Revenue per employee$1.29Mvs $405.05K
Profit per employee$149.26Kvs -$704.12K

The grey tick and the second figure are the median of companies in the same industry group; green means this company is on the better side of it.

How fast it is growing

Trailing twelve months against a year earlier, and the compound annual rate over three and five fiscal years

Last 12 months3-year, a year5-year, a yearIndustry median

What it owes and what covers it

Latest balance sheet, against twelve months of cash generation

Cash and short-term investments exceed every borrowing by $86.80M. That is 30.4% of the $285.90M it would cost to buy the business outright.

Total debt$0
Cash and short-term investments$86.80M
EBITDA, trailing twelve months$40.92M
Free cash flow, trailing twelve months$41.16M

Leverage and liquidity

Debt to equity0.00vs 0.50
Debt to EBITDA0.00vs 3.42
Net debt to EBITDA-2.12vs 2.33
Debt to free cash flow0.00vs 4.83
Current ratio2.91vs 3.28
Quick ratio2.43vs 2.37

The grey tick and the second figure are the median of companies in the same industry group; green means this company is on the better side of it.

Scores and rules of thumb

Academic scores computed from the latest two fiscal years. They are screens, not verdicts.

Altman Z-Score

Five ratios that together predicted bankruptcy within two years.

-2.85
DistressGrey zoneSafe

Piotroski F-Score

Nine yes-or-no tests of profit, leverage and efficiency against last year.

8 of 9 tests passed

Beneish M-Score

Eight variables that flag accounts shaped to look better than they are.

-2.06
No flagManipulation risk

Price against two rules of thumb

Graham's number and Lynch's fair value, both derived from current earnings.

Graham $5.60Price $7.22

What comes back to shareholders

Trailing twelve months against the market value at the latest close

Earnings yield7.17%vs -23.6%
Free cash flow yield11.0%vs -9.69%

The grey tick and the second figure are the median of companies in the same industry group; green means this company is on the better side of it.

How the shares have traded

Total return includes reinvested dividends, to the close on Nov 18, 2026

$4.7952-week low52-week high$11.50
$7.22200-day20-day50-day

The close sits 36% of the way up the 52-week range, 37.2% below the high.

Relative strength index, 14 days

How much of the recent move has been upward. Extremes are where traders look for a turn.

26
OversoldNeutralOverbought

Total return against the S&P 500

The axis is compressed: each step is ten times the one before, so a month and a decade fit on the same line.

PBYIS&P 500
PeriodPBYIS&P 500DifferencePBYI per yearS&P 500 per year
1 month-26.6%-4.3%−22.2 pts
3 months-21.9%-4.6%−17.2 pts
Year to date+21.3%+7.9%+13.4 pts
1 year+42.7%+11.8%+30.9 pts
3 years+87.5%+68.0%+19.6 pts+23.3%+18.9%
5 years+114.2%+66.2%+48.0 pts+16.5%+10.7%
10 years-83.3%+291.3%−374.6 pts-16.4%+14.6%

How much it moves

Beta against the S&P 5000.99vs 1.07
Volatility, 1 year52.8%vs 80.6%
Volume against its 90-day average1.26vs 0.87

The grey tick and the second figure are the median of companies in the same industry group; green means this company is on the better side of it.

Who is betting against it

Shares sold short and not yet covered, reported by brokers to FINRA twice a month. Latest settlement date Oct 30, 2026.

4M PBYI shares were sold short on Oct 30, 2026, down 5.3% from the previous report, or 10.27% of the shares available to trade. At recent volumes it would take 11.5 days to buy them back. Over the last 20 sessions, 57.2% of the volume reported to FINRA was short selling.

Shares sold shortDays to cover
Short interest as a share of the float10.3%vs 8.89%
Short interest as a share of all shares8.33%vs 6.30%
Days of volume to buy it back11.51vs 5.13

The grey tick and the second figure are the median of companies in the same industry group; green means this company is on the better side of it.

The last twelve reports

Settlement dateShares shortChangeAvg. daily volumeDays to cover
Oct 30, 20264,298,038-5.3%373,51311.5
Oct 15, 20264,540,314+6.5%352,63912.9
Sep 30, 20264,264,923-1.3%304,28914.0
Sep 15, 20264,319,663+1.1%313,11913.8
Aug 31, 20264,274,524+2.6%273,61015.6
Aug 14, 20264,167,830+1.0%365,78111.4
Jul 31, 20264,126,395+5.6%297,12713.9
Jul 15, 20263,909,380+7.7%367,13210.7
Jun 30, 20263,628,478-1.9%428,3678.5
Jun 15, 20263,698,796-2.7%200,92818.4
May 29, 20263,803,328-9.3%192,76819.7
May 15, 20264,194,225+2.2%355,79011.8

Every measure, in full

101 figures from SEC filings and the closing price. Hover a name for the formula; the last column is the median of companies in the same industry group.

Important dates

Next earnings
Feb 25, 2027 (estimated, after the close)
Last ex-dividend date
No dividends
Fundamentals through
Jun 30, 2026
Share price as of
Nov 18, 2026

Valuation ratiosIndustry

Market Cap
$372.70M
$248.90M
Enterprise Value
$285.90M
$131.42M
PE Ratio
13.88
23.40
PS Ratio
1.61
3.72
PB Ratio
2.69
1.96
P/TBV Ratio
2.69
2.22
P/FCF Ratio
9.06
18.75
P/OCF Ratio
9.06
13.27

Enterprise valuationIndustry

EV / Sales
1.24
2.35
EV / EBITDA
6.99
15.88
EV / EBIT
9.39
18.60
EV / FCF
6.95
21.06

Share statisticsIndustry

Shares Change (YoY)
3.74%
11.0%
Shares Change (QoQ)
0.44%
0.58%
Float
42M
49M
Shares Held by Insiders
18.9%
11.1%
Shares Held by Institutions
74.9%
56.3%

Short sellingIndustry

Short Interest
4M
–
Short Interest Change
-5.34%
-0.80%
Short % of Float
10.3%
8.89%
Short % of Shares Outstanding
8.33%
6.30%
Days to Cover
11.51
5.13

Stock price statisticsIndustry

52-Week High
$11.50
–
52-Week Low
$4.79
–
20-Day Moving Average
$9.35
–
50-Day Moving Average
$9.63
–
200-Day Moving Average
$8.04
–
Average True Range (14)
$0.51
–
Price Change (1 Week)
-10.6%
-9.92%
Price Change (1 Month)
-32.9%
-10.4%
Price Change (3 Months)
-20.7%
-26.0%
Price Change (6 Months)
3.29%
-24.7%
Price Change (YTD)
21.3%
-26.8%
Price Change (1 Year)
45.6%
-24.8%
Price Change (3 Years)
87.5%
-32.3%
Price Change (5 Years)
111.1%
-77.8%
Price Change (10 Years)
-83.3%
-67.7%
Average Volume (10 Days)
597,078
–
Average Volume (20 Days)
492,722
–
Average Volume (90 Days)
360,504
–
Relative Volume
1.26
0.87
Relative Strength Index (14)
25.6
40.4
Volatility (1 Year)
52.8%
80.6%
Beta (5 Years)
0.99
1.07

MarginsIndustry

Gross Margin
74.8%
52.8%
Operating Margin
13.2%
-42.9%
Pretax Margin
13.5%
-13.0%
Profit Margin
11.6%
-39.9%
EBITDA Margin
17.7%
-29.3%
FCF Margin
17.8%
-9.41%

Returns on capitalIndustry

Return on Equity (ROE)
22.0%
-53.3%
Return on Assets (ROA)
13.8%
-40.6%
Return on Invested Capital (ROIC)
42.7%
-31.9%
Return on Capital Employed (ROCE)
21.3%
-38.7%

Financial positionIndustry

Current Ratio
2.91
3.28
Quick Ratio
2.43
2.37
Debt / Equity
0.00
0.50
Debt / EBITDA
0.00
3.42
Debt / FCF
0.00
4.83
Net Debt / EBITDA
-2.12
2.33
Interest Coverage
8.65
-6.08

GrowthIndustry

Revenue Growth (YoY)
-2.86%
5.81%
Net Income Growth (YoY)
-44.9%
-31.1%
EPS Growth (YoY)
-46.9%
-25.8%
FCF Growth (YoY)
-6.93%
3.26%
Revenue Growth (3Y CAGR)
0.05%
2.25%
Revenue Growth (5Y CAGR)
0.29%
6.41%

EfficiencyIndustry

Asset Turnover
1.19
0.39
Inventory Turnover
5.31
2.68
Revenue Per Employee
$1.29M
$405.05K
Profits Per Employee
$149.26K
-$704.12K
Employee Count
179
75
WACC
10.0%
10.2%

Income statement (TTM)Industry

Revenue
$231.24M
$58.79M
Gross Profit
$173.05M
$103.58M
Operating Income
$30.44M
-$21.49M
Pretax Income
$31.17M
-$14.83M
Net Income
$26.72M
-$22.47M
EBITDA
$40.92M
-$17.14M
EPS (Diluted)
$0.52
-$0.83

Balance sheetIndustry

Total Debt
$0
$114.91M
Net Cash (Debt)
$86.80M
$15.31M
Net Cash Per Share
$1.68
$0.72
Equity (Book Value)
$138.54M
$49.40M
Book Value Per Share
$2.68
$1.45
Tangible Book Value
$138.54M
$23.58M
Working Capital
$95.25M
$74.34M

Cash flow (TTM)Industry

Operating Cash Flow
$41.15M
-$12.15M
Capital Expenditures
$10.00K
-$1.02M
Free Cash Flow
$41.16M
-$20.44M
FCF Per Share
$0.80
-$0.42

Dividends and yieldsIndustry

Earnings Yield
7.17%
-23.6%
FCF Yield
11.0%
-9.69%

Taxes and interestIndustry

Interest Expense
$3.52M
$3.07M

Scores and fair valueIndustry

Graham Number
$5.60
$19.07
Graham Upside
-22.4%
-46.9%
Altman Z-Score
-2.85
0.11
Piotroski F-Score
8
4
Beneish M-Score
-2.06
-2.62

Ratios use trailing-twelve-month results and the latest balance sheet. How we calculate.

See a number that looks wrong?